Navigation Links
Hospira Names John B. Elliot Senior Vice President of Operations
Date:4/11/2012

LAKE FOREST, Ill., April 11, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that John B. Elliot has been named senior vice president, Operations, effective April 16. In this role, Mr. Elliot will have overall responsibility for Hospira's global operations organization and serve as a member of Hospira's senior leadership team. He will report directly to F. Michael Ball, chief executive officer.

"John is a seasoned global leader with more than 35 years of broad manufacturing experience across production, logistics and supply, and specific expertise in injectable pharmaceuticals," said Mr. Ball. "With his proven track record in driving improvements in quality, service and operational effectiveness, we're confident John will have an immediate, positive impact as we continue our efforts to deliver high-quality, cost-effective products to customers and ultimately establish our manufacturing operations as a strategic, competitive advantage."

Mr. Elliot, 60, has most recently advised some of the world's largest pharmaceutical companies in his role as an operations consultant. He previously served as president and chairman at Cherokee Pharmaceuticals, LLC (subsequently acquired by Merck & Co.), a U.S.-based active ingredients manufacturing company, where he led the organization from start-up to become a significant competitor in the contract manufacturing marketplace. Prior to Cherokee, Mr. Elliot spent 26 years with GlaxoSmithKline plc (formerly SmithKline Beecham), most recently serving as senior vice president. During his tenure, he held various roles of progressive responsibility in the operations organization and was credited for inculcating a high-performance culture across his plant network.

Under Mr. Elliot's leadership, Hospira wi
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hospira Names Zena G. Kaufman Senior Vice President of Quality; Strengthens Quality and Compliance Capabilities With Addition of Top Industry Talent
2. Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement
3. Hospira Receives Favorable Court Decision on Eloxatin(R)
4. Hospira Announces Plans to Integrate Symbiq(R) and EndoTool(R) Technologies
5. Hospira Names Brian Meadows Supply Chain Chief
6. Hospira Supports Newly Introduced Biogenerics Legislation
7. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
8. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
9. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
10. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
11. Health Diagnostic Laboratory Names Scott Blackwell Vice President of Corporate Culture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., ... has filed a Clinical Trial Application (CTA) with the ... Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical ... Anatabine Citrate. Contingent on the Company receiving ... Phase I trial to assess the safety, tolerability and ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... DIEGO , Dec. 22, 2014 GenomeDx ... the Decipher Prostate Cancer Classifier, a genomic test for ... in node-negative, high-risk men managed by radical prostatectomy without ... radical prostatectomy is relatively uncommon, using tumor genomics to ... of metastatic disease is an important advance. The study ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... BALTIMORE, June 14, 2011 Arcion Therapeutics , ... therapies for chronic pain, today announced that data from ... of pain associated with painful diabetic neuropathy (PDN) will ... medical meetings.  The first poster will be presented at ...
... PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in Boston, MA.  James Winschel, Sr. Vice President ... PAREXEL at 2:00 p.m. ET on Wednesday, June 22, 2011. ... available through the "Investors" section of PAREXEL,s website ...
... 2011 /PRNewswire-Asia/ -- TWi Biotechnology Inc. announced today ... the total 240 patients for the Phase IIb ... Type II Diabetes. The randomized, double-blind, placebo-controlled, dose-ranging, ... glycated hemoglglobin A1c (HbA1c) lowering effects of AC-201 ...
Cached Biology Technology:Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 2Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 3PAREXEL International to Present at Wells Fargo Healthcare Conference 2Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes 2
(Date:12/22/2014)... 2014  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES ... Apollo Robbins will be at the ... demonstrating some of his famous theft techniques to visiting ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014 /PRNewswire/ ... the publication of a study that pinpoints fine-scale differences ... the United States . Since immigrants ... the United States has served as ... study illuminates how American history and the ongoing mixing ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Columbia have been able to pinpoint more of the ... valuable compounds to the roasting process. Lead author ... the prevailing antioxidants present in dark roasted coffee brew ... high temperatures. Their findings will appear in ...
... Zaragoza (UNIZAR) has studied precipitation trends in Spain,s 10 ... results show that precipitation has declined overall between the ... the rainy season. The rains are heavier in October ... 1946, the average precipitation falling on Spanish hydrological basins ...
... a serious environmental, economic and social problem worldwide as ... ecosystem functions, such as nutrient cycling. Despite substantial research, ... new habitats over native plants that technically should have ... is that these plants are more abundant in introduced ...
Cached Biology News:Roasting coffee beans a dark brown produces valued antioxidants: UBC food scientists 2Rain in Spain is on the decline 2Home and away: How do invasive plant species dominate native species? 2
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
... array sample elements. , , ,Includes: , , ... in PBS (10X): 50 ml , Streptavidin ... 8 packs , 10% Tween-20: 2 x 10 ... x 25 ml , SuperSignal West Pico Stable Peroxide: ...
... polyclonal antibody raised against a ... Immunogen: XAGE2 (NP_570133, ... partial recombinant protein with GST ... Number: NM_130777 ...
...
Biology Products: